Abstract
To explore whether differences existed between the use of (Elonva®) and gonadotrophin releasing hormone (GnRH) agonist for triggering and the traditional stimulation schema with recombinant FSH and human chorionic gonadotrophin (hCG) for triggering in terms of efficacy, safety and patient friendliness in oocytes donation cycles.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
